2017 Archived Content

MONDAY, 13 NOVEMBER | 09:00 - 12:00 | MORNING

TRANSIENT PROTEIN EXPRESSION: 
A KEY TOOL TO ENABLE RAPID PROTEIN ENGINEERING

This short course introduces both the fundamental concepts and technologies needed to establish transient protein production in mammalian cells, which has become an essential tool to enable rapid protein engineering. Transient expression allows for the rapid generation, purification and characterization of milligram-to-gram quantities of secreted or intracellular recombinant proteins for therapeutic, functional and structural studies. The course combines instruction and case studies in an interactive environment.

Instructors:

Richard Altman, MS, Scientist V, Protein Technologies, Amgen

Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research



DETAILED AGENDA:

09:00 Opening Remarks/Introductions

Richard Altman, MS, Scientist V, Protein Technologies, Amgen

09:05 Fundamental Elements of Transient Protein Production

Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

  • Available transient expression systems
  • DNA vector elements for enhanced protein production

10:00 Fundamental Elements of Transient Protein Production

Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

  • HEK293 vs. CHO
  • The interplay of cells, medium, transfection reagent, and supplements
  • Key considerations for maximizing yields

10:30 Coffee Break

10:50 Fundamental Elements of Transient Protein Production (cont.)

Henry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific  

11:15 Implementing Transient Protein Production

Richard Altman, MS, Scientist V, Protein Technologies, Amgen

  • What are your goals/objectives for transient protein expression?
  • Case studies 
    • Assembling an effective mammalian expression toolbox
    • Optimizing the total protein expression process
     

12:00 Close of Course


Instructors Biographies:

Altman RichardRichard Altman, MS, Scientist V, Protein Technologies, Amgen

Rich Altman has 29 years of experience working in the pharmaceutical industry. In 2016, he joined the Protein Technologies Mammalian Expression group at Amgen San Francisco, supporting biologics drug development. Prior to Amgen, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.

Chiou HenryHenry C. Chiou, Ph.D., Associate Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific

Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years he has worked as a principal scientist and now in product development and portfolio management for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.

Esposito DominicDominic Esposito, Ph.D., Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on producing Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on mutant Ras genes including structural biology, biophysics and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his Ph.D. in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.